Literature DB >> 10695710

The immunopathogenesis of Miller Fisher syndrome.

H J Willison1, G M O'Hanlon.   

Abstract

Over the past decade, remarkable progress has been made in our understanding of the pathogenesis of Miller Fisher syndrome (MFS), a clinical variant of Guillain Barré syndrome (GBS). MFS comprises the clinical triad of ataxia, areflexia and ophthalmoplegia. It is associated with acute-phase IgG antibodies to GQ1b and GT1a gangliosides in over 90% of cases which are highly disease specific. Like GBS, MFS is a post-infectious syndrome following diverse infections, but particular attention has been paid to its association with Campylobacter jejuni enteritis. Serostrains of C. jejuni isolated from infected patients bear ganglioside-like epitopes in their lipopolysaccharide core oligosaccharides, which elicit humoral immune responses exhibiting molecular mimicry with GQ1b/GT1a gangliosides. These antibodies are believed to be the principal cause of the syndrome and physiological studies aimed at proving this have focused on the motor-nerve terminal as a potential site of pathogenic action. This review describes these findings and formulates a pathogenesis model based on our current state of knowledge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695710     DOI: 10.1016/s0165-5728(99)00213-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  28 in total

1.  Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis.

Authors:  Ilya V Yepishin; Randall Z Allison; David A Kaminskas; Natalia M Zagorski; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2016-07

2.  Posterior column involvement in Miller Fisher syndrome or dorsal root ganglion neuronopathy?

Authors:  Hai-feng Li; Yan-chen Xie
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

3.  Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth.

Authors:  Gang Zhang; Helmar C Lehmann; Sowmia Manoharan; Mohammedali Hashmi; Sangwoo Shim; Guo-Li Ming; Ronald L Schnaar; Pablo H Lopez; Nataliia Bogdanova; Kazim A Sheikh
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 4.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

5.  Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Authors:  Emilien Delmont; P Y Jeandel; A M Hubert; L Marcq; J Boucraut; C Desnuelle
Journal:  J Neurol       Date:  2009-12-04       Impact factor: 4.849

Review 6.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

7.  Comparative characterization of the virulence gene clusters (lipooligosaccharide [LOS] and capsular polysaccharide [CPS]) for Campylobacter coli, Campylobacter jejuni subsp. jejuni and related Campylobacter species.

Authors:  Vincent P Richards; Tristan Lefébure; Paulina D Pavinski Bitar; Michael J Stanhope
Journal:  Infect Genet Evol       Date:  2012-12-29       Impact factor: 3.342

8.  Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function.

Authors:  Roland W M Bullens; Graham M O'Hanlon; Eric Wagner; Peter C Molenaar; Keiko Furukawa; Koichi Furukawa; Jaap J Plomp; Hugh J Willison
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

9.  Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis.

Authors:  E Ece Boylu; R Erdem Toğrol; Mehmet Güney Senol; M Fatih Ozdağ; Mehmet Saraçoğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

10.  Acute bilateral ophthalmoparesis with pupilary areflexical mydriasis in miller-fisher syndrome treated with intravenous immunoglobulin.

Authors:  Theocharis Papanikolaou; Cath Gray; Bernard Boothman; Gerald Naylor; George Mariatos
Journal:  J Ophthalmol       Date:  2010-09-01       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.